Contemporary view on neuromonitoring following severe traumatic brain injury

John F Stover

John F Stover, Surgical Intensive Care Medicine, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland

Author contributions: Stover JF solely contributed to this paper.

Correspondence to: John F Stover, MD, Professor, Surgical Intensive Care Medicine, University Hospital Zürich, Rämistrasse 100, 8091 Zürich, Switzerland. john.stover@access.uzh.ch

Received: June 3, 2011 Revised: October 27, 2011 Accepted: December 21, 2011 Published online: February 4, 2012

Abstract

Evolving brain damage following traumatic brain injury (TBI) is strongly influenced by complex pathophysiologic cascades including local as well as systemic influences. To successfully prevent secondary progression of the primary damage we must actively search and identify secondary insults e.g. hypoxia, hypotension, uncontrolled hyperventilation, anemia, and hypoglycemia, which are known to aggravate existing brain damage. For this, we must rely on specific cerebral monitoring. Only then can we unmask changes which otherwise would remain hidden, and prevent adequate intensive care treatment. Apart from intracranial pressure (ICP) and calculated cerebral perfusion pressure (CPP), extended neuromonitoring (SjvO₂, ptiO₂, microdialysis, transcranial Doppler sonography, electrocorticography) also allows us to define individual pathologic ICP and CPP levels. This, in turn, will support our therapeutic decision-making and also allow a more individualized and flexible treatment concept for each patient. For this, however, we need to learn to integrate several dimensions with their own possible treatment options into a complete picture. The present review summarizes the current understanding of extended neuromonitoring to guide therapeutic interventions with the aim of improving intensive care treatment following severe TBI, which is the basis for ameliorated outcome.

INTRODUCTION

Severe traumatic brain injury (TBI) is associated with a high risk of mortality and persistent deficits, which may preclude successful reintegration, thereby having dramatic consequences not only for the individual patient but also for society due to the tremendous socio-economic burden involved.

To prevent additional damage to the already injured and highly vulnerable brain, especially during the early posttraumatic phase, specific knowledge is essential. An in-depth understanding of interwoven pathophysiologic cascades must be complemented by specific neuromonitoring. Only then can we unmask the presence and extent of typical secondary insults caused by e.g. hypoxia, hypotension, uncontrolled hyperventilation, anemia, and hypoglycemia, which are known to aggravate existing brain damage. Since secondary insults strongly determine quality of survival, it is of utmost importance to prevent these secondary insults. There is increasing evidence which clearly shows that we cannot rely on intracranial pressure (ICP) and cerebral perfusion pressure (CPP) alone to assess additional tissue damage. Therefore, extended neuromonitoring has become indispensable in modern intensive care to unmask otherwise occult signs of cerebral impairment, and during phases of normal ICP.
diagnosing signs of secondary deterioration, extended neuromonitoring may be helpful in adapting the quality and extent of our therapeutic interventions. In addition to basic neuromonitoring consisting of ICP and CPP, extended bedside neuromonitoring refers to transcranial Doppler/Duplex sonography (TCD), jugular venous oxygen saturation (SjvO$_2$), partial tissue oxygen pressure (ptiO$_2$), and cerebral microdialysis to unmask changes in brain metabolism (glucose, lactate, pyruvate, glutamate, glycerol), and electrocorticography to determine cortical spreading depression (CSD) (Figure 1).

Overall, it is important to refrain from only interpreting one parameter as the different parameters are interwoven and functionally interdependent. Thus, it is important to consider several dimensions simultaneously, integrating e.g. ptiO$_2$, cerebral glucose, CPP, paco$_2$, and hematocrit. Correct interpretation of these results within the context of the individual situation requires lots of experience in overall clinical management and neuromonitoring. Progressive insight into previously hidden changes which can only be unmasked with extended neuromonitoring is the basis for improved treatment, hopefully resulting in improved outcome following severe TBI.

**BASIC NEUROMONITORING**

**ICP and CPP**

Increased intracranial volume reflected by elevated ICP is the primary parameter used to judge cerebral deterioration during pharmacologic coma. A persistent increase in ICP can induce and maintain a vicious circle[1]. It is important to acknowledge that a normal ICP does not guarantee absence of pathologic processes, especially in conditions in which the ICP cannot be assessed adequately e.g. following craniectomy, CSF leakage, subdural air entrapment, or even sensor malfunctioning. New data clearly show that metabolic and functional alterations unmasked by extended neuromonitoring precede increases in ICP[2].

A very simple measure to indirectly estimate global cerebral perfusion is to calculate CPP = mean arterial blood pressure (MABP) - ICP. A “normal” CPP, however, does not guarantee sufficient cerebral perfusion and oxygenation. To define an optimal CPP leading to optimal cerebral perfusion, other parameters e.g. ptiO$_2$, SjvO$_2$, brain metabolism (e.g. glucose, lactate, lactate to pyruvate ratio) and flow velocity must be integrated. Using extraventricular drainage combined with pressure recording allows us to combine diagnostic and therapeutic options by measuring ICP and draining cerebrospinal fluid to reduce elevated ICP, respectively. Extraventricular drainage, however, is associated with an albeit small risk of additional injury to periventricular structures, hemorrhages, and local infections[3].

**Jugular venous oxygen saturation and arterio-jugular venous differences**

To assess global cerebral perfusion, oxygen consumption, and metabolic state analysis of SjvO$_2$, various metabolic indices (e.g. oxygen-glucose index, lactate-oxygen index, lactate-glucose index), oxygen extraction ratio, and arterio-jugular venous lactate difference have proven helpful at the bedside[4,5]. SjvO$_2$ correlates directly with perfusion and correlates inversely with cerebral oxygen consumption. Thus, SjvO$_2$ can be used to guide therapeutic interventions, including modulation of MABP and CPP, controlling hyperventilation, guiding oxygen administration, and influencing the extent of pharmacologic coma and hypothermia.

**Tissue oxygenation - ptiO$_2$**

Measuring ptiO$_2$ not only reflects local changes, but also unmasks cerebral consequences of systemic influences e.g. blood pressure, oxygenation, and anemia. This, in turn, allows us to guide the type and extent of therapeutic interventions[6,7]. Similar to changes in SjvO$_2$, ptiO$_2$ values indirectly reflect cerebral perfusion and oxygenation[8], while low SjvO$_2$ and ptiO$_2$ values unmask reduced cerebral perfusion with cerebral ischemia at SjvO$_2$ < 50% and ptiO$_2$ < 10 mmHg. High SjvO$_2$ (> 80%) and ptiO$_2$ values (> 30 mmHg) unmask impaired oxygen consumption en-
countered under conditions of hyperemia/ luxury perfusion.

It is important to correct \( \text{pito}_2 \) values < 10 mmHg (Licox \(^\text{®} \)) within 30 min to prevent hypoxia-induced increase in glutamate \(^{[9,10]} \), neuropsychologic deficits \(^{[11]} \), and poorer outcome with increased mortality \(^{[12]} \).

**Cerebral microdialysis**

Changes in cerebral metabolism assessed by measuring glucose, lactate, pyruvate, glycerol, glutamate, and by calculating the lactate to pyruvate ratio, a marker of hypoxic/ischemic metabolic impairment \(^{[13,14]} \), both follow as well as precede increases in ICP \(^{[2,15]} \). Pathologic alterations reflected by low glucose and elevated lactate to pyruvate ratio were recently identified to significantly predict mortality following severe TBI \(^{[16]} \). In addition, increased lactate to pyruvate ratio was associated with subsequent chronic frontal lobe atrophy \(^{[18]} \), possibly giving rise to subsequent dementia. Overall, metabolic monitoring can also be used to guide therapeutic interventions to correct e.g. hypotension, hyperemia, vasospasm, hyperventilation, fever, epileptic discharges, hypoglycemia, and anemia. The integration of cerebral microdialysis was an integral part of the “Lund concept” allowing a reduction in CPP levels as low as 50 mmHg \(^{[17]} \), thereby substantially influencing treatment options. For best results in potentially optimizing our current therapy, metabolic monitoring using cerebral microdialysis must be combined with other parameters e.g. pito2, Sjvo2, and CPP.

**TCD**

TCD can unmask conditions of low flow \(^{[18]} \), vasospasm, and hyperemia. Each of these conditions, in turn, will require differential therapeutic interventions: vasospasm requires controlled hypertension and normo- to hyperventilation; hyperemia requires controlled hypotension and hyperventilation; low flow requires increased cardiac output especially in conjunction with bradycardia. The cerebral blood flow velocity determined within the large basal cerebral arteries can be used to reflect regional cerebral perfusion, cerebral autoregulation, and CO2-reactivity \(^{[19]} \). In addition, calculating e.g. the pulsatility index and resistance index allow the non-invasive estimation of ICP and CPP \(^{[20,21]} \). This proves helpful when an ICP probe cannot be inserted due to coagulation disorder or if an ICP probe is damaged. This allows us to bridge the time until a new ICP probe can be inserted. However, an ICP probe needs to be replaced as soon as possible since only continuous ICP readings can be used to reliably adapt therapeutic interventions.

**CSD**

CSD involving neuronal and glial energy-consuming depolarization \(^{[22]} \) as well as a spreading wave of ischemia and vasoconstriction with subsequent vasodilation \(^{[23]} \), contributes to the secondary growth of a pre-existing lesion \(^{[24,25]} \) and is associated with decreased cerebral glucose, increased lactate to pyruvate ratio, and elevated lactate \(^{[26,27]} \). CSD can be induced by elevated extracellular potassium, decreased cerebral NO levels and reduced blood and brain glucose concentrations \(^{[28,29]} \). CSD requires the introduction of a special sensor which is positioned under the dura directly on the cortical surface. At present, it is unclear which patients with which lesions will profit from the application of these sensors.

**LIMITATIONS**

Any neuromonitoring technique is limited by certain restraints making compromises indispensable. Similar to ICP, regional metabolic heterogeneity exists even within the same hemisphere depending on the extension of the lesion and the positioning of the probes relative to the lesion \(^{[30,31]} \). Despite the introduction of multiple probes within the supratentorial compartment the infratentorial areas are not assessed. To prevent additional damage, deep structures such as the basal ganglia are not penetrated under clinical conditions. Furthermore, we must also face local changes at different depths along the probes. To avoid inadequate decision-making the catheters and probes should not be positioned within the core of a contusion as this necrotic tissue will always reveal pathologic values. The consensus recommendation is to place the catheters and probes within the pericontusional tissue to successfully unmask progressive lesion growth, metabolic worsening, and impaired perfusion which may be reversible and amenable to treatment options (Figure 2). In the case of diffuse brain injury, the probes should be positioned within the more severely injured hemisphere. Nonetheless, signs of impaired cerebral metabolism are found even in regions without obvious signs of structural damage. This functional impairment can result from increased ICP due to local changes and can be induced by systemic influences due to e.g. hypotension, hyperemia, vasospasm, hyperventilation, fever, epileptic discharges, hypoglycemia, and anemia.

It is important to acknowledge that local and global monitoring does not exclude each other but successfully extends our insight into otherwise occult changes. In this context, pito2 and Sjvo2 closely reflect each other \(^{[40]} \) and arterio-jugular venous glucose differences have been shown to correspond to local changes in cerebral glucose determined by cerebral microdialysis \(^{[33]} \). Despite these limitations, local as well as global parameters should be monitored in patients with severe TBI who are subjected to pharmacologic coma. Categorically omitting neuromonitoring is a mistake as we deprive ourselves of important information, which is decisive in adapting and modulating our therapeutic interventions. At present, it is difficult to define to what extent basic or extended neuromonitoring significantly determines quality of outcome. In theory, we may expect that the substantial increase in our knowledge using neuromonitoring will translate to improved treatment. By strictly integrating Sjvo2, pito2, microdialysis, and TCD we are able to individualize the extent, aggressiveness, and duration of therapeutic inter-
Interventions, thereby reducing the frequency of barbiturate coma, secondary craniectomies, pulmonary dysfunction, and significantly reducing the rate of red blood cell transfusions and associated costs in patients subjected to prolonged pharmacologic coma.

**WHAT IS THE IMPACT OF EXTENDED NEUROMONITORING IN ROUTINE INTENSIVE CARE?**

While basic neuromonitoring includes neurologic examination, computerized tomography, and ICP, extended neuromonitoring comprises $\text{SjvO}_2$, $\text{ptiO}_2$, microdialysis, TCD, and electrophysiologic recordings including CSD.

Extended neuromonitoring in daily clinical practice helps to improve our treatment options by characterizing functional influences, defining threshold values, and adapting therapeutic interventions in type, extent and duration. In addition, extended neuromonitoring helps us to prevent induction of additional brain damage due to excessive therapeutic corrections. In this context, aggressive volume administration aimed at improving cerebral perfusion was associated with a sustained risk of acute respiratory distress syndrome and abdominal compartment syndrome. Furthermore, excessive ventilatory support to increase $\text{paO}_2$ can induce additional pulmonary damage, aggressive lowering of arterial blood glucose to prevent hyperglycemia-induced cell damage increases the frequency and extent of hypoglycemic episodes, and a categorical transfusion regimen to improve cerebral oxygenation may be associated with transfusion-related complications.

When only relying on changes in ICP and CPP, we may not only miss important signs of deterioration, but also fail to adequately reduce therapeutic interventions. Based on current evidence, extended neuromonitoring is important to determine optimal CPP, guide oxygenation and ventilation, influence transfusion practice, define optimal blood and brain glucose, and even guide decompressive craniectomy.

**GUIDANCE FOR CPP**

Calculating CPP does not guarantee adequate cerebral perfusion. Assessing $\text{ptiO}_2$ is indispensable in determining optimal cerebral perfusion as CPP significantly influences $\text{ptiO}_2$. $\text{ptiO}_2$ can be used to determine the lower still acceptable CPP value. Several studies have convincingly shown that the generally recommended CPP threshold of 60 mmHg is insufficient and that even “normal” CPP values cannot protect from cerebral hypoxia and impaired metabolism. Furthermore, regional heterogeneity is characterized by different requirements reflected by different levels of CPP-dependent $\text{ptiO}_2$ values. In this context, normal CPP of approximately 70 mmHg is insufficient for the perifocal tissue compared to normal appearing tissue in which $\text{ptiO}_2$ was significantly higher. Advancing from observational to interventional studies, integrating $\text{ptiO}_2$ in clinical routine by using a $\text{ptiO}_2$-supplemented ICP- and CPP-based treatment protocol significantly kept ICP < 20 mmHg, improved outcome judged by the Glasgow Outcome Scale, and reduced mortality rate compared to the standard ICP/CPP-directed therapy.

![Figure 3 Illustrative case showing the influence of enteral nutrition on arterial blood and brain glucose levels. Based on low brain glucose, enteral nutrition was gradually increased resulting in elevated blood and brain glucose. Due to surgery, enteral nutrition was stopped. This resulted in a decrease in blood and brain glucose. Restarting of enteral nutrition increased blood and brain glucose again.](image-url)
With the help of monitoring brain metabolism using cerebral microdialysis, CPP can be reduced to low values e.g. 50 mmHg without causing additional brain damage\[^17\]. In this context, lactate and the calculated lactate to pyruvate ratio unmask insufficient cerebral perfusion and oxygen delivery leading to energetic and metabolic impairments\[^{17,43}\]. As shown using the “Lund concept” to treat patients with severe TBI, microdialysis must be included to allow a reduction in CPP providing the therapeutic concept is practiced as published\[^{17}\]. Improving cerebral perfusion and correcting anemia has been shown to successfully normalize brain lactate to pyruvate ratio, glyceral, and glutamate levels\[^43\]. Whether this is valid for all lesion types is unclear.

**GUIDANCE FOR VENTILATORY SUPPORT: OXYGENATION AND VENTILATION**

Integrating ptiO\(_2\) and SjvO\(_2\) in clinical routine can be used to individually define paO\(_2\) and paCO\(_2\) targets. These individual targets, in turn, can be used to adjust ventilatory settings, thereby preventing ventilation-induced lung injury and hemodynamic instability.

**Oxygenation**

Elevating the fraction of inspired oxygen (FiO\(_2\)) significantly increased ptiO\(_2\)\[^{16,40}\] and reduced cerebral lactate\[^{38}\]. However, increasing ptiO\(_2\) too aggressively by normobaric hypoxia (FiO\(_2\): 1.0) was associated with decreased cerebral blood flow despite improved brain metabolism. This impaired perfusion coincided with worse outcome 3 mo after TBI. As shown under experimental conditions, increasing oxygen supply alone is insufficient to improve cerebral oxygenation if impaired cerebral perfusion is not corrected adequately\[^{48}\].

**Hyperventilation**

Although hyperventilation is an easy and helpful therapeutic intervention to decrease elevated ICP\[^{46}\], hyperventilation can induce additional secondary ischemic brain damage\[^{47}\] due to hypocapnia-induced vasoconstriction. This impaired perfusion, in turn, results in metabolic and neurochemical alterations reflected by reduced ptiO\(_2\) and SjvO\(_2\) and elevated extracellular glutamate and lactate\[^{48}\]. Interestingly, even small changes in paCO\(_2\) within normal limits are detrimental\[^{49}\]. Consequently, extended neuromonitoring should also be performed in patients during anticipated normoventilation. It is essential to control hyperventilation by using appropriate neuromonitoring techniques to unmask signs of cerebral ischemia due to hyperventilation-induced vasoconstriction, because normal ICP levels achieved by hyperventilation will cause us to miss relevant pathologic processes within the brain. Reduced SjvO\(_2\), decreased ptiO\(_2\), and signs of metabolic impairment (lactate, glutamate, lactate to pyruvate ratio)\[^{50,51}\] aid in assessing the lowest possible individual paCO\(_2\) level\[^{52,56}\]. This helps us to avoid active induction of secondary brain damage.

**GUIDANCE FOR RED BLOOD CELL TRANSFUSIONS**

Cerebral oxygenation is influenced by the number of circulating oxygen carriers, i.e. red blood cells (hematocrit). At present, the optimal hematocrit following severe TBI is controversial. A fast reduction in hematocrit known to significantly reduce cerebral oxygen supply\[^{37}\] must be avoided. Under controlled critical care conditions with stable CPP and stable oxygenation and ventilation, ptiO\(_2\) can be used to define the transfusion threshold\[^{59}\]. Patients with a ptiO\(_2\) > 15 mmHg do not profit from red blood cell transfusion\[^{59}\]. A transfusion of red blood cells in patients with a hematocrit < 30% and a concomitant ptiO\(_2\) value below 15 mmHg was able to persistently increase ptiO\(_2\) > 15 mmHg\[^{59}\]. At the same time, CPP must be maintained above 60 mmHg to prevent cerebral hypoxia determined by ptiO\(_2\)\[^{59}\]. These data show that ptiO\(_2\) can be used to reliably assess the individual transfusion threshold.

**GUIDANCE FOR OPTIMAL BLOOD AND BRAIN GLUCOSE**

Mitochondrial damage, aggravated oxidative stress, impaired neutrophil function, reduced phagocytosis, and diminished intracellular destruction of ingested bacteria are deleterious consequences of hyperglycemia. Elevated blood glucose > 9.4 mmol/L (> 169 mg/dL) is associated with sustained mortality and morbidity\[^{60-63}\]. These deleterious consequences can be prevented by normalizing elevated blood glucose levels. Maintaining blood glucose levels within tight limits between 4.4 mmol/L and 6.1 mmol/L (80 to 110 mg/dL)\[^{62}\], however, is hampered by the risk of hypoglycemia and a strong variation in blood glucose levels\[^{63}\], which was associated with sustained mortality\[^{62,64,65}\]. Reducing blood glucose to 4.4-6.1 mmol/L significantly increased extracellular glutamate levels and elevated lactate to pyruvate ratio, reflecting excessive neural excitation and metabolic perturbation\[^{64}\]. Decreased blood glucose and low cerebral extracellular glucose levels were even associated with sustained mortality\[^{67}\] and induction of CSD at low blood glucose levels < 5 mmol/L\[^{28,68,69}\]. To define individual blood and brain glucose, void of any deleterious metabolic consequences, extended neuromonitoring is indispensable. In this context, reduced cerebral oxygen consumption, reduced lactate and CO\(_2\) production, increased glucose uptake, elevated cerebral glucose and decreased lactate to pyruvate ratio were observed at arterial blood glucose levels between 6 mmol/L and 9 mmol/L\[^{32}\]. Based on cerebral microdialysis, insulin should not be given at arterial blood glucose levels < 5 mmol/L as this significantly increased extracellular glutamate and lactate to pyruvate ratio. At arterial
blood glucose levels > 9 mmol/L, insulin administration is encouraged to significantly increase cerebral glucose levels and reduce lactate to pyruvate ratio. Based on data obtained by microdialysis, brain glucose should remain above 1 mmol/L since cerebral glucose < 1 mmol/L was associated with increased lactate to pyruvate ratio. Persistently low brain glucose levels were also associated with electrographic seizures, nonspecific reductions in CPP, decreased SjvO₂, increased glutamate levels, and poor outcome. Expanding the assessment of brain glucose from mere monitoring to integration into clinical decision-making allows us to guide adaptation of nutritional support, which is a simple measure to increase both blood as well as brain glucose concentrations (Figure 3). Overall, nutritional support has been shown to improve hormonal status and clinical outcome in patients with TBI.

GUIDANCE FOR DECOMPRESSIVE CRANIECTOMY

For patients with uncontrollable intracranial hypertension, decompressive craniectomy with dura enlargement has been shown to improve cerebral perfusion, oxygenation, and metabolism, reflected by increased ptiO₂, decreased lactate to pyruvate ratio, reduced glycerol and glutamate levels. Several reports have shown that pathologic neuro-monitoring precedes clinical deterioration. This, in turn, underscores the importance of integrating extended neuromonitoring in clinical routine to support decision-making on when to perform a decompressive craniectomy.

CONCLUSION

In the contemporary intensive care of patients with severe TBI subject to pharmacologic coma, basic monitoring using only ICP and CPP should be expanded by extended neuromonitoring including e.g. SjvO₂, ptiO₂, microdialysis, TCD, and electrocorticography. Growing evidence clearly supports the integration of extended neuromonitoring to unmask otherwise occult alterations and to differentially adapt the type, extent, and duration of our therapeutic interventions. By expanding our knowledge and experience, the integration of extended neuromonitoring in daily clinical routine will provide us with the means to improve outcome, which has not been possible by relying on ICP and CPP values alone as practiced in the past.

REFERENCES

1. Smith M. Monitoring intracranial pressure in traumatic brain injury. Anesthesiol 2000; 106: 240-248
2. Belli A, Sen J, Petzold A, Russo S, Kitchen N, Smith M. Metabolic failure precedes intracranial pressure rises in traumatic brain injury: a microdialysis study. Acta Neurochir (Wien) 2008; 150: 461-469; discussion 470
3. Saladino A, White JB, Wijdicks EF, Lanzino G. Malplacement of ventricular catheters by neurosurgeons: a single institution experience. Neurocrit Care 2009; 10: 248-252
4. Möller K, Paulson OB, Hornbein TF, Colier WN, Paulson AS, Roach RC, Holm S, Knudsen GM. Unchanged cerebral blood flow and oxidative metabolism after acclimatization to high altitude. J Cereb Blood Flow Metab 2002; 22: 118-126
5. Holbein M, Bechrir M, Ludwig S, Sommerfeld J, Cottini SR, Keel M, Stocker R, Stover JF. Differential influence of arterial blood glucose on cerebral metabolism following severe traumatic brain injury. Crit Care 2009; 13: R13
6. Kiening KL, Unterberg AW, Bardt TF, Schneider GH, Lanksch WR. Monitoring of cerebral oxygenation in patients with severe head injuries: brain tissue PO2 versus jugular vein oxygen saturation. J Neurosurg 1996; 85: 751-757
7. Roseenthal G, Hemphill JC, Sorani M, Martin C, Morabito D, Obrist WD, Manley GT. Brain tissue oxygen tension is more indicative of oxygen diffusion than oxygen delivery and metabolism in patients with traumatic brain injury. Crit Care Med 2006; 34: 1917-1924
8. Jaeger M, Seehle M, Schuhmann MU, Winkler D, Meixensberger J. Correlation of continuously monitored regional cerebral blood flow and brain tissue oxygen. Acta Neurochir (Wien) 2005; 147: 51-56; discussion 56
9. Sarrafzadeh AS, Sakowitz OW, Callisen TA, Lanksch WR, Unterberg AW. Bedside microdialysis for early detection of cerebral hypoxia in traumatic brain injury. Neurosurg Focus 2000; 9: e2
10. Meixensberger J, Kunze E, Barcay E, Vaeth A, Roosen K. Clinical cerebral microdialysis: brain metabolism and brain tissue oxygenation after acute brain injury. Neurol Res 2001; 23: 801-806
11. Meixensberger J, Renner C, Simanowski R, Schmidtke A, Dings J, Roosen K. Influence of cerebral oxygenation following severe head injury on neuropsychological testing. Neurol Res 2004; 26: 414-417
12. Maloney-Wilensky E, Gracias V, Ikin A, Hoffman K, Bloom S, Yang W, Christian S, LeRoUX PD. Brain tissue oxygen and outcome after severe traumatic brain injury: a systematic review. Crit Care Med 2009; 37: 2057-2063
13. Tisdall MM, Smith M. Cerebral microdialysis: research technique or clinical tool. Br J Anaesth 2006; 97: 18-25
14. Vespa P, Bergsneider M, Hattori N, Wu HM, Huang SC, Martin NA, Glenn TC, McAuliffe DL, Hovda DA. Metabolic crisis without brain ischemia is common after traumatic brain injury: a combined microdialysis and positron emission tomography study. J Cereb Blood Flow Metab 2005; 25: 763-774
15. Timofeev I, Carpenter KL, Nortje J, Al-Rawi PG, O’Connell MT, Czosnyka M, Smielewski P, Pickard JD, Menon DK, Kirkpatrick PJ, Gupta AK, Hutchinson PJ. Cerebral extracellular chemistry and outcome following traumatic brain injury: a microdialysis study of 223 patients. Brain 2011; 134: 484-494
16. Marcoux J, McArthur DA, Miller C, Glenn TC, Villablanca P, Martin NA, Hovda DA, Alger JR, Vespa PM. Persistent metabolic crisis as measured by elevated cerebral microdialysis lactate-pyruvate ratio predicts chronic frontal lobe brain atrophy after traumatic brain injury. Crit Care Med 2008; 36: 2871-2877
17. Nordström CH, Reinstrup P, Xu W, Gårdenfors A, Ungerstedt U. Assessment of the lower limit for cerebral perfusion pressure in severe head injuries by bedside monitoring of regional energy metabolism. Anesthesiology 2003; 98: 809-814
18. van Santbrink H, Schouten JW, Steyerberg EW, Avezat CJ, Maas Ai. Serial transcranial Doppler measurements in traumatic brain injury with special focus on the early posttraumatic period. Acta Neurochir (Wien) 2002; 144: 1141-1149
19. Rasulo FA, De Peri E, Lavinio A. Transcranial Doppler ultrasound in intensive care. Eur J Anaesthesiol Suppl 2008; 42: 167-173
Transfusion in the critically ill: does it affect outcome? Crit Care Med 2008; 36: 2619-2625

Stover JF. Neuromonitoring for traumatic brain injury

20 Moppett IK, Mahajan RP. Transcranial Doppler ultrasonography in anaesthesia and intensive care. Br J Anaesth 2004; 93: 710-724

21 Brauer G, Béchir M, Sailer S, Haberbürh C, Stocker R, Stover JF. Transcranial color-coded duplex sonography allows to assess cerebral perfusion pressure noninvasively following severe traumatic brain injury. Acta Neurochir (Wien) 2010; 152: 965-972

22 LEAO AA. Further observations on the spreading depression of activity in the cerebral cortex. J Neurophysiol 1947; 10: 409-414

23 Brennan KC, Beltrán-Parrazal L, López-Valdés HE, Theriot J, Ioga AW, Charles AC. Distinct vascular conduction with cortical spreading depression. J Neurophysiol 2007; 97: 4143-4151

24 Dreier JP, Woitzik J, Fabricius M, Bhatia R, Major S, Drenckhahn C, Lehmann TN, Sarrafzadeh A, Willumsen L, Hartings JA, Sakowitz OW, Seemann JH, Thieme A, Lautritzen M, Strong AJ. Delayed ischaemic neurological deficits after subarachnoid haemorrhage are associated with clusters of spreading depolarizations. Brain 2006; 129: 3224-3237

25 Fabricius M, Fuhr S, Bhatia R, Boutelle M, Hashemi P, Strong AJ, Lautritzen M. Cortical spreading depression and peri-infarct depolarization in acutely injured human cerebral cortex. Brain 2006; 129: 778-790

26 Krajewski KL, Orackioglu B, Haux D, Hertle DN, Santos E, Kiening KL, Unterberg AW, Sakowitz OW. Cerebral microdialysis in acutely brain-injured patients with spreading depolarizations. Acta Neurochir Suppl 2011; 110: 125-130

27 Feuerstein D, Manning A, Hashemi P, Bhatia R, Fabricius M, Tolias C, Pahl C, Ervine M, Strong AJ, Boutelle MG. Dynamic metabolic response to multiple spreading depolarizations in patients with acute brain injury: an online microdialysis study. J Cereb Blood Flow Metab 2010; 30: 1343-1355

28 Strong AJ, Hartings JA, Dreier JP. Cortical spreading depression: an adverse but treatable factor in intensive care? Curr Opin Crit Care 2007; 13: 126-133

29 Parkin M, Hopwood S, Jones DA, Hashemi P, Landolt H, Fabricius M, Lautritzen M, Boutelle MG, Strong AJ. Dynamic changes in brain glucose and lactate in pericontusional areas of the human cerebral cortex, monitored with rapid sampling on-line microdialysis: relationship with depolarization-like events. J Cereb Blood Flow Metab 2005; 25: 402-413

30 Sahuquillo J, Poca MA, Arribas M, Garnacho A, Rubio E, Meléndez V, Theobald D, Alberola-López C, Berliner J, Toga AW, Charles AC. Distinct vascular conduction with cortical spreading depression. J Neurosurg Anesthesiol 2009; 21: R13

31 Engström M, Polito A, Reinstrup P, Romner B, Ryding E, Ungerstedt U, Nordström CH. Intracerebral microdialysis in severe brain trauma: the importance of catheter location. J Neurosurg 2005; 102: 460-469

32 Meierhans R, Béchir M, Ludwig S, Sommerfeld J, Brandi G, Haberbürh C, Stocker R, Stover JF. Brain metabolism is significantly impaired at blood glucose below 6 mM and brain lactate below 1 mM in patients with severe traumatic brain injury. Crit Care 2010; 14: R13

33 Robertson CS, Valadka AB, Hannay HJ, Contant CF, Gopinath SP, Cormio M, Uzura M, Grossman RG. Prevention of secondary ischemic insults after severe head injury. Crit Care Med 1999; 27: 2086-2095

34 An G, West MA. Abdominal compartment syndrome: a concise clinical review. Crit Care Med 2008; 36: 1304-1310

35 Pinheiro de Oliveira R, Hetzel MP, dos Anjos Silva M, Dallegevrande D, Friedman G. Mechanical ventilation with high tidal volume induces inflammation in patients without lung disease. Crit Care 2010; 14: R39

36 Meier R, Béchir M, Ludwig S, Sommerfeld J, Keel M, Steiger P, Stocker R, Stover JF. Differential temporal profile of lowered blood glucose levels (3.5 to 6.5 mmol/l versus 5 to 8 mmol/l) in patients with severe traumatic brain injury. Crit Care 2008; 12: R98

37 Cannon-Diehl MR. Transfusion in the critically ill: does it affect outcome? Crit Care Nurs Q 2010; 33: 324-338

38 Reintert M, Barth A, Rothen HS, Schaller B, Takala J, Seiler RW. Effects of cerebral perfusion pressure and increased fraction of inspired oxygen on brain tissue oxygen, lactate and glucose in patients with severe head injury. Acta Neurochir (Wien) 2003; 145: 341-349; discussion 349-350

39 Marin-Caballos AJ, Murillo-Cabezas F, Cayuela-Dominguez A, Dominguez-Roldán JM, Rincón-Ferrari MD, Valencia-Anguita J, Flores-Cordero JM, Muñoz-Sánchez MA. Cerebral perfusion pressure and risk of brain hypoxia in severe head injury: a prospective observational study. Crit Care 2005; 9: R670-R676

40 Longhi L, Pagan F, Valerniani V, Magnoni S, Zanier ER, Con te V, Branca V, Stocchetti N. Monitoring brain tissue oxygen tension in brain-injured patients reveals hypoxic episodes in normal-appearing and in peri-focal tissue. Intensive Care Med 2007; 33: 2136-2142

41 Narotam PK, Morrison JF, Nathoo N. Brain tissue oxygen monitoring in traumatic brain injury and major trauma: outcome analysis of a brain tissue oxygen-directed therapy. J Neurosurg 2009; 111: 672-682

42 Spiotta AM, Stiefel MF, Gracias VH, Garufte AM, Kofke WA, Maloney-Wilensky E, Troxel AB, Levine JM, Le Roux PD. Brain tissue oxygen-directed management and outcome in patients with severe traumatic brain injury. J Neurosurg 2010; 113: 571-580

43 Stähl N, Schalen W, Ungerstedt U, Nordström CH. Bedside biochemical monitoring of the penumbra zone surrounding an evacuated acute subdural haematoma. Acta Neuro Scand 2003; 108: 211-215

44 Menzel M, Doppenberg EM, Zauner A, Soukop J, Reintert MM, Clausen T, Brockenbrough PB, Bullock R. Cerebral oxygenation in patients after severe head injury: monitoring and effects of arterial hyperoxia on cerebral blood flow, metabolism and intracranial pressure. J Neurosurg Anesthesiol 1999; 11: 240-251

45 Rossi S, Stocchetti N, Longhi L, Balestrieri M, Spagnoli D, Zanier ER, Bellinzona G. Brain oxygen tension, oxygen supply, and oxygen consumption during arterial hyperoxia in a model of progressive cerebral ischemia. J Neurotrauma 2001; 18: 163-174

46 Stocchetti N, Maas AI, Chiaregato A, van der Plas AA. Hyperventilation in head injury: a review. Chest 2005; 127: 1811-1827

47 Muizelaar JP, Marmarou A, Ward JD, Kontos HA, Choi SC, Becker DP, Gruener H, Young HF. Adverse effects of prolonged hyperventilation in patients with severe head injury: a randomized clinical trial. J Neurosurg 1991; 75: 731-739

48 Davis DP. Early ventilation in traumatic brain injury. Resuscitation 2008; 76: 333-340

49 Hutchinson PJ, Gupta AK, Fryer TF, Al-Rawi PG, Chatterton DA, Coles JP, O’Connell MT, Kett-White R, Minhas PS, Aigbirhio FI, Clark JC, Kirkpatrick PJ, Menon DK, Packard JD. Correlation between cerebral blood flow, substrate delivery, and metabolism in head injury: a combined microdialysis and triple oxygen positron emission tomography study. J Cereb Blood Flow Metab 2002; 22: 735-745

50 Sarrafzadeh AS, Kiening KL, Callisen TA, Unterberg AW. Metabolic changes during impending and manifest cerebral hypoxia in traumatic brain injury. Br J Neurosurg 2003; 17: 340-346

51 Marion DW, Puccio A, Wisniewski SR, Kochanek P, Dixon CE, Bullian L, Carlier P. Effect of hyperventilation on extracellular concentrations of glutamate, lactate, pyruvate, and local cerebral blood flow in patients with severe traumatic brain injury. J Cereb Blood Flow Metab 2002; 30: 2619-2625

52 Unterberg AW, Kiening KL, Härtl R, Bardt T, Sarrafzadeh AS, Lanksch WR. Multimodal monitoring in patients with...
head: evaluation of the effects of treatment on cerebral oxygenation. *J Trauma* 1997; 42: 552-567

53 **Soukup J**, Bramsiepe I, Brucke M, Sanchin L, Menzel M. Evaluation of a bedside monitor of regional CBF as a measure of CO2 reactivity in neurosurgical intensive care patients. *J Neurosurg Anesthesiol* 2008; 20: 249-255

54 **Soustiel JF**, Mahamid E, Chistyakov A, Shik V, Benenson R, Zaatoo M. Comparison of moderate hyperperfusion and mannotol for control of intracranial pressure control in patients with severe traumatic brain injury--a study of cerebral blood flow and metabolism. *Acta Neurochir* (Wien) 2006; 148: 845-851; discussion 851

55 **Carmona Suarez JA**, Maas AJ, van den Brink WA, van Santbrink H, Steyerberg EW, Avezaat CJ. CO2 reactivity and brain oxygen pressure monitoring in severe head injury. *Crit Care Med* 2000; 28: 3268-3274

56 **Ekeland A**, Reintrop P, Ryding E, Andersson AM, Molund T, Kristiansson KA, Romner B, Brandt L, Säveland H. Effects of iso- and hypervolemic hemodilution on regional cerebral blood flow and oxygen delivery for patients with vasospasm after aneurysmal subarachnoid hemorrhage. *Acta Neurochir* (Wien) 2002; 144: 703-712; discussion 712-713

57 **Smith MJ**, Stiefel MF, Magge S, Frangos S, Bloom S, Gracias V, Le Roux PD. Packed red blood cell transfusion increases local cerebral oxygenation. *Crit Care Med* 2005; 33: 1104-1108

58 **Leal-Noval SR**, Rincón-Ferrari MD, MarinNiebla A, Cayuela A, Arellano-Orden V, Marin-Caballós A, Amaya-Villar R, Ferrándiz-Million C, Muriño-Cabeza F. Transfusion of erythrocyte concentrates produces a variable increment on cerebral oxygenation in patients with severe traumatic brain injury: a preliminary study. *Intensive Care Med* 2006; 32: 1733-1740

59 **Chang JJ**, Youn BS, Benson D, Mattick H, Andrade N, Harpman MJ, Lui TN, Binns CW, Chiu WT. Early Enteral Nutrition and Clinical Outcomes of Severe Traumatic Brain Injury Patients in Acute Stage: A Multi-Center Cohort Study. *J Neurotrauma* 2011; Epub ahead of print

60 **Chourdasakis K**, Kraus MM, Tzellos T, Sarderi C, Peftoulidou M, Vassilakos D, Kouvelas D. Effect of Early Compared With Delayed Enteral Nutrition on Endocrine Function in Patients With Traumatic Brain Injury: An Open-Labeled Randomized Trial. *JPEN J Parenter Enteral Nutr* 2011; Epub ahead of print

61 **Stover JF**. Neuromonitoring for traumatic brain injury

values without altering glucose utilization or improving the lactate/pyruvate ratio after traumatic brain injury. *Crit Care Med* 2006; 34: 850-856

67 **Oddo M**, Schmiedt JM, Carrera E, Badjatia N, Connolly ES, Presciutti M, Oztukovkivich ND, Levine JM, Le Roux P, Mayer SA. Impact of tight glycometric control on cerebral glucose metabolism after severe brain injury: a microdialysis study. *Crit Care Med* 2008; 36: 3233-3238

68 **Strong AJ**, Smith SE, Whittington DJ, Meldrum BS, Parsons AA, Krupinski J, Hunter AJ, Patel S, Robertson C. Factors influencing the frequency of fluorescence transients as markers of peri-infarct depolarizations in focal cerebral ischemia. *Stroke* 2000; 31: 214-222

69 **Hopwood SE**, Parkin MC, Bezzina EL, Boutelle MG, Strong AJ. Transient changes in cortical glucose and lactate levels associated with peri-infarct depolarisations, studied with rapid-sampling microdialysis. *J Cereb Blood Flow Metab* 2005; 25: 391-401

70 **Béchir M**, Meierhans R, Brandl G, Sommerfeld J, Fasshauer M, Cottini SR, Stocker R, Stover JF. Insulin differentially influences brain glucose and lactate in traumatic brain injured patients. *Minerva Anestesiol* 2010; 76: 896-904

71 **Vespa PM**, McArthur D, O’Phelan K, Glenn T, Etchepare M, Kelly D, Bergsneider M, Martin NA, Hovda DA. Persistently low extracellular glucose correlates with poor outcome 6 months after human traumatic brain injury despite a lack of increased lactate: a microdialysis study. *J Cereb Blood Flow Metab* 2003; 23: 865-877

72 **Chiang YH**, Chao DP, Chu SF, Lin HW, Huang SY, Yeh YS, Lui TN, Binns CW, Chiu WT. Early Enteral Nutrition and Clinical Outcomes of Severe Traumatic Brain Injury Patients. *J Neurol Neurosurg Psychiatry* 2003; 74: 513-528

73 **Jeremitsky E**, Omer LT, Dunham CM, Wilberger J, Rodrigueuz A. The impact of hyperglycemia on patients with severe brain injury. *J Trauma* 2005; 58: 47-50

74 **van den Bergh G**, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. *N Engl J Med* 2001; 345: 1359-1367

75 **Bilotta F**, Caramia R, Cernak I, Paoloni FP, Doroconio A, Cuzzzone V, Santoro A, Rosa G. Intensive insulin therapy after severe traumatic brain injury: a randomized clinical trial. *Neurocrit Care* 2008; 9: 159-166

76 **van den Bergh G**, Wilmer A, Hermans G, Meersseman W, Wouters PJ, Milants I, Van Wijngaerden E, Bobbaers H, Bouillon R. Intensive insulin therapy in the medical ICU. *N Engl J Med* 2006; 354: 449-461

77 **van den Bergh G**, Schoonheydt K, Becx P, Bruyninckx F, Wouters PJ. Insulin therapy protects the central and peripheral nervous system of intensive care patients. *Neurology* 2005; 64: 1348-1353

78 **Vespa P**, Boonyaputthikul R, McArthur DL, Miller C, Etchepare M, Bergsneider M, Glenn T, Martin N, Hovda D. Intensive insulin therapy reduces microdialysis glucose